

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮嚙健康科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 09886)

(1) RESIGNATION OF EXECUTIVE DIRECTOR AND VICE PRESIDENT; AND (2) APPOINTMENT OF EXECUTIVE DIRECTOR AND VICE PRESIDENT

The Board hereby announces that, with effect from February 16, 2026:

1. Mr. Yu Lei has tendered his resignation as an executive Director and the vice president of the Company and all positions in the Group; and
2. Mr. MENG Fanzhou has been appointed as an executive Director and the vice president of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) hereby announces the following changes of the Board.

RESIGNATION OF EXECUTIVE DIRECTOR AND VICE PRESIDENT

The Board hereby announces that Mr. Yu Lei (“**Mr. Yu**”) has tendered his resignation as an executive Director and the vice president of the Company and all positions in the Group with effect from February 16, 2026 due to personal career development plans and related reasons. Mr. Yu has confirmed that he has no disagreement with the Board, and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders (the “**Shareholders**”) of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Yu for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. MENG Fanzhou (“**Mr. MENG**”) has been appointed as an executive Director and the vice president of the Company with effect from February 16, 2026.

The biographical details of Mr. MENG are set out as follows:

Mr. MENG, aged 43, joined the Group in August 2015. He is the vice president of Dingdang Medicine Express Technology Group Ltd. (an integrated affiliated entity and the holding company of all other integrated affiliated entities of the Group) (“**Dingdang Medicine Express Technology**”) and a director of certain subsidiaries of the Group. He is responsible for the daily operation and management of Dingdang Medicine Express Technology. From April 2013 to February 2015, Mr. MENG served as the operation director of Lefeng.com (Shanghai) Information Technology Co., Ltd.

Mr. MENG obtained his college diploma in economics (project management) through online education from Beihang University in Beijing, the PRC, in July 2013.

Mr. MENG has entered into a service contract with the Company for an initial term of three years with effect from February 16, 2026, which is renewable automatically for successive terms of three years commencing on the day after the expiry of the then existing term and may be terminated by not less than 3 months’ notice in writing served by either party on the other. Mr. MENG will hold office until the first annual general meeting of the Company after his appointment and be eligible for re-election in accordance with the articles of association of the Company. Mr. MENG does not receive any director’s fees as an executive Director, except for the corresponding remuneration for his other positions in the Group.

As at the date of this announcement, pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”), Mr. MENG is interested in an aggregate of 2,300,000 shares of the Company, comprising (i) 2,000,000 restricted shares granted to him under Restricted Share Scheme adopted by the Company on May 1, 2020; and (ii) 300,000 restricted share units granted to him under the 2023 Restricted Share Unit Scheme adopted by the Company on June 27, 2023.

Save as disclosed above, as at the date of this announcement, Mr. MENG (a) does not have any interests in the shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO; (b) does not hold any directorships in any other listed public companies in Hong Kong or overseas in the last three years preceding the date of his appointment, and does not hold any other major appointments and professional qualifications; (c) does not have any relationships with any Director, senior management, substantial shareholder or controlling shareholder of the Company (as defined under the Listing Rules); and (d) does not hold any other position with the Company or any members of the Group.

Save as disclosed above, there is no other matters which need to be brought to the attention of the Shareholders of the Company regarding the appointment of Mr. MENG or any other information which is required to be disclosed pursuant Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to express its warm welcome to Mr. MENG for joining the Board.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
Chairman
YANG WENLONG

Hong Kong, February 16, 2026

As at the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. YANG Yibin, Mr. XU Ning, Mr. YU Qinglong and Mr. MENG Fanzhou, the non-executive Director is Ms. LI Chuheng, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.